Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-003526-92-FR
EUCTR2013-003526-92-FR
Active, not recruiting
Not Applicable

see below - GLUCIMAG-2

INSERM0 sitesDecember 10, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy VolunteersTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy Volunteers
Sponsor
INSERM
Status
Active, not recruiting
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 10, 2013
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
INSERM

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 20
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisMedDRA version: 21.0Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859Therapeutic area: Diseases [C] - Immune System Diseases [C20]
CTIS2023-505127-31-00IGM Biosciences Inc.24
Active, not recruiting
Phase 1
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune ThrombocytopeniaPrimary immune thrombocytopenia (ITP)MedDRA version: 23.0Level: PTClassification code: 10083842Term: Immune thrombocytopenia Class: 100000004851Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
CTIS2023-508819-23-00Hutchmed Ltd.51
Active, not recruiting
Not Applicable
/A
EUCTR2011-000221-68-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Completed
Phase 2
EuroSkinGraft - Novomaix phase II A phase 2, intra-patient randomised controlled multicentre international study to evaluate the efficacy of an acellular dermal template Novomaix for the treatment of full thickness skin defects.Full thickness skin defectsscar problems1001498210040795
NL-OMON41095niversity of Zurich - Tissue Biology Research Unit15
Recruiting
Phase 1
A multicenter, Phase 1b, double-blind, placebo-controlled study to evaluate the safety and tolerability, and the efficacy of si-544 in adults with psoriasis vulgaris or psoriatic arthritis
CTIS2023-507393-40-00selectION Therapeutics GmbH40